ADR3, a next generation i-body to human RANKL, inhibits osteoclast formation and bone resorption
Open Access
- 9 January 2023
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (2) , 102889
Abstract
No abstract availableKeywords
Funding Information
- The University of Western Australia
- National Health and Medical Research Council (APP1107828, APP1127156, APP1163933)
This publication has 53 references indexed in Scilit:
- Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory ActivityJournal of Biological Chemistry, 2013
- V-ATPases in osteoclasts: Structure, function and potential inhibitors of bone resorptionThe International Journal of Biochemistry & Cell Biology, 2012
- Disorders of Bone RemodelingAnnual Review of Pathology: Mechanisms of Disease, 2011
- Structure-based development of a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosisProceedings of the National Academy of Sciences, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- NFATc1 Induces Osteoclast Fusion Via Up-Regulation of Atp6v0d2 and the Dendritic Cell-Specific Transmembrane Protein (DC-STAMP)Molecular Endocrinology, 2008
- A TNF receptor loop peptide mimic blocks RANK ligand–induced signaling, bone resorption, and bone lossJournal of Clinical Investigation, 2006
- Tissue-specific and Ubiquitous Promoters Direct the Expression of Alternatively Spliced Transcripts from the Calcitonin Receptor GeneJournal of Biological Chemistry, 2001
- Carbonic anhydrase II is an AP‐1 target gene in osteoclastsJournal of Cellular Physiology, 2001
- Characterization of the mouse tartrate-resistant acid phosphatase (trap) gene promoterJournal of Bone and Mineral Research, 1995